AR048643A1 - Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms) - Google Patents
Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms)Info
- Publication number
- AR048643A1 AR048643A1 ARP050101746A ARP050101746A AR048643A1 AR 048643 A1 AR048643 A1 AR 048643A1 AR P050101746 A ARP050101746 A AR P050101746A AR P050101746 A ARP050101746 A AR P050101746A AR 048643 A1 AR048643 A1 AR 048643A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- halogen
- group
- alkyl
- amino
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 230000001548 androgenic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 32
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- -1 hydroxy, carboxy Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente se refiere a derivados de indol como moduladores selectivos de los receptores androgénicos (SARMS), composiciones farmacéuticas que los contienen y su uso en el tratamiento de trastornos y afecciones moduladas por el receptor de androgenos. Reivindicacion 1: Un compuesto de formula (1) donde X se selecciona del grupo integrado por O, S y NR1; R1 se selecciona del grupo integrado por H, alquilo inferior, alquilo inferior fluorado, -SO2-(alquilo inferior), -SO2-fenilo, -SO2- tolilo, -(CH2)-(alquilo inferior fluorado), -(alquilo inferior)-CN, -(alquilo inferior)-C(O)-O-(alquilo inferior), -(alquilo inferior)-O-(alquilo inferior) y -(alquilo inferior)-S(O)0-2-(alquilo inferior); R4 se selecciona del grupo integrado por H, halogeno, alquilo inferior, alquenilo inferior, alquinilo inferior y ciano; donde el alquilo inferior, alquenilo inferior o alquinilo inferior están opcionalmente sustituidos sobre el átomo de C termal con -Si(alquilo inferior)3; a es un entero de 0 a 4; R5 se selecciona del grupo integrado por halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, alcoxi inferior sustituido con halogeno, ciano, nitro, amino, alquilamino inferior, di(alquilo inferior)amino, -C(O)-(alquilo inferior), -C(O)-(alcoxi inferior), -C(O)-N(RA)2, -S(O)0-2-(alquilo inferior), -SO2-N(RA)2, -N(RA)-C(O)-(alquilo inferior), -N(RA)-C(O)-(alquilo inferior sustituido con halogeno) y arilo; donde cada RA se selecciona independientemente de H o alquilo inferior; donde el arilo está opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, alcoxi inferior sustituido con halogeno, ciano, nitro, amino, alquilamino inferior o di(alquilo inferior)amino; b es un entero de 0 a 1; c es un entero de 0 a 1; R7 se selecciona del grupo integrado por H, alquilo inferior y -Si(alquilo inferior)3; El anillo (A) es una estructura de anillo saturado o parcialmente insaturado de 4 a 7 miembros, que contiene 1 a 2 heteroátomos seleccionados de O, N o S; donde la estructura de anillo saturado o parcialmente insaturado de 4 a 7 miembros está opcionalmente sustituida con un sustituyente seleccionado de -(L1)0-1-R8; donde L1 se selecciona del grupo integrado por -(CH2)1-4-, -C(O)-, -C(O)-(CH2)1-4-, -C(O)O- y -C(O)O-(CH2)1-4; donde R8 se selecciona del grupo integrado por arilo y heteroarilo, donde el arilo o heteroarilo están opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente del grupo integrado por halogeno, hidroxi, carboxi, alquilo inferior, alquilo inferior sustituido con halogeno, alcoxi inferior, ciano, nitro, amino, alquilamino inferior, di(alquilo inferior)amino, -S(O)0-2-(alquilo inferior) y -SO2-N(RA)2; siempre que cuando X es NH o N(CH3), R4 es H, b es 0, c es 0, R7 es H o metilo y a es 0, entonces el anillo (A) es diferente de piperidinilo, donde el piperidinilo está opcionalmente sustituido con alquilo inferior o aralquilo; o su sal aceptable para uso farmacéutico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56776304P | 2004-05-03 | 2004-05-03 | |
| US11/096,664 US7282507B2 (en) | 2004-05-03 | 2005-04-01 | Indole derivatives as selective androgen receptor modulators (SARMS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048643A1 true AR048643A1 (es) | 2006-05-10 |
Family
ID=34965787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101746A AR048643A1 (es) | 2004-05-03 | 2005-05-02 | Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7282507B2 (es) |
| EP (1) | EP1753749B1 (es) |
| JP (1) | JP5070042B2 (es) |
| CN (1) | CN1980917B (es) |
| AR (1) | AR048643A1 (es) |
| AU (1) | AU2005243240B2 (es) |
| CA (1) | CA2564952A1 (es) |
| MY (1) | MY142850A (es) |
| TW (1) | TW200606146A (es) |
| WO (1) | WO2005111028A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029852T2 (en) | 2004-03-15 | 2017-04-28 | Janssen Pharmaceutica Nv | Opioid receptor modulators |
| ES2371170T3 (es) * | 2004-05-03 | 2011-12-28 | Janssen Pharmaceutica Nv | Derivados de benzofurano comomoduladores selectivos de receptores de andrógenos (msra). |
| CN101374808B (zh) * | 2006-01-24 | 2011-05-25 | 伊莱利利公司 | 孕酮受体的吲哚磺酰胺调节剂 |
| US8238515B2 (en) * | 2007-08-16 | 2012-08-07 | Caldera Pharmaceuticals, Inc. | Well plate |
| MX2010009162A (es) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| CA2788907A1 (en) | 2010-02-04 | 2011-08-11 | Radius Health, Inc. | Selective androgen receptor modulators |
| PT2568806T (pt) | 2010-05-12 | 2016-08-05 | Radius Health Inc | Regimes terapêuticos |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| ES2550319T3 (es) | 2010-09-28 | 2015-11-06 | Radius Health, Inc | Moduladores selectivos del receptor de andrógenos |
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| HRP20180061T1 (hr) | 2012-07-17 | 2018-02-23 | Glaxosmithkline Intellectual Property (No. 2) Limited | Indolkarbonitrili kao selektivni modulatori androgenskih receptora |
| RS67458B1 (sr) | 2014-03-28 | 2025-12-31 | Univ Duke | Lečenje kancera dojke pozitivnog na receptor estrogena upotrebom selektivnih modulatora receptora estrogena |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| RS63311B1 (sr) | 2016-06-22 | 2022-07-29 | Ellipses Pharma Ltd | Ar+ metode lečenja raka dojke |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| SG11202011135WA (en) | 2018-05-14 | 2020-12-30 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN112423844B (zh) | 2018-07-04 | 2024-08-13 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
| JOP20210218A1 (ar) | 2019-02-12 | 2023-01-30 | Radius Pharmaceuticals Inc | عمليات ومركبات |
| US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20230160299A (ko) | 2021-03-23 | 2023-11-23 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체 표적화 화합물 |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN115028655B (zh) * | 2022-05-20 | 2024-01-16 | 上海大学 | 一种2-三氟甲基-3-碘-吲哚类化合物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4129655A (en) * | 1976-04-26 | 1978-12-12 | Ciba-Geigy Corporation | Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans |
| WO1994020459A2 (en) * | 1993-03-01 | 1994-09-15 | Merck Sharp & Dohme Limited | Pyrrolo-pyridine derivatives as dopamine receptor ligands |
| GB9605065D0 (en) * | 1996-03-11 | 1996-05-08 | Merck Sharp & Dohme | Therapeutic agents |
| US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| DE69942801D1 (de) * | 1998-05-26 | 2010-11-11 | Chugai Pharmaceutical Co Ltd | Heterozyklische indolderivate und mono- oder diazaindol-derivate |
| JP2000086603A (ja) * | 1998-07-15 | 2000-03-28 | Yoshitomi Pharmaceut Ind Ltd | 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体 |
| PL353792A1 (en) * | 1999-08-27 | 2003-12-01 | Ligand Pharmaceuticals Incorporatedligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
| EP1214312B1 (en) * | 1999-09-09 | 2004-04-14 | H. Lundbeck A/S | 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| EP1250336B1 (en) * | 1999-12-20 | 2004-05-12 | Eli Lilly And Company | Piperidine derivatives and their use as serotonin receptor antagonists |
| GB0003257D0 (en) * | 2000-02-11 | 2000-04-05 | Darwin Discovery Ltd | Heterocyclic compounds and their therapeutic use |
| US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| EP1334106B1 (en) * | 2000-11-17 | 2006-05-24 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, production method thereof and use thereof |
-
2005
- 2005-04-01 JP JP2007511374A patent/JP5070042B2/ja not_active Expired - Fee Related
- 2005-04-01 CN CN200580022206.3A patent/CN1980917B/zh not_active Expired - Fee Related
- 2005-04-01 AU AU2005243240A patent/AU2005243240B2/en not_active Ceased
- 2005-04-01 EP EP05735409.4A patent/EP1753749B1/en not_active Expired - Lifetime
- 2005-04-01 US US11/096,664 patent/US7282507B2/en not_active Expired - Lifetime
- 2005-04-01 CA CA002564952A patent/CA2564952A1/en not_active Abandoned
- 2005-04-01 WO PCT/US2005/011106 patent/WO2005111028A1/en not_active Ceased
- 2005-04-29 TW TW094113779A patent/TW200606146A/zh unknown
- 2005-04-29 MY MYPI20051938A patent/MY142850A/en unknown
- 2005-05-02 AR ARP050101746A patent/AR048643A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1753749A1 (en) | 2007-02-21 |
| CN1980917B (zh) | 2014-02-12 |
| AU2005243240A1 (en) | 2005-11-24 |
| JP5070042B2 (ja) | 2012-11-07 |
| CA2564952A1 (en) | 2005-11-24 |
| US20050245485A1 (en) | 2005-11-03 |
| US7282507B2 (en) | 2007-10-16 |
| AU2005243240B2 (en) | 2012-03-15 |
| MY142850A (en) | 2011-01-14 |
| TW200606146A (en) | 2006-02-16 |
| CN1980917A (zh) | 2007-06-13 |
| EP1753749B1 (en) | 2014-07-30 |
| WO2005111028A1 (en) | 2005-11-24 |
| JP2007536227A (ja) | 2007-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
| AR119651A1 (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington | |
| AR004225A1 (es) | Derivados de indolin-2-ona, su uso, un procedimiento para prepararlos, composiciones farmaceuticas que los comprenden y compuestos utiles como intermediarios para preparar dichos derivados | |
| AR040030A1 (es) | Moduladores biciclicos de la funcion del receptor de androgeno | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| CO6140056A2 (es) | Compuestos amino -5-4(difluorometoxi)fenil sustituido-5-fenilimidazolona como inhibidores de beta -secretasa | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR055360A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR073412A1 (es) | Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende. | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| AR048723A1 (es) | Derivados de indol como moduladores selectivos del receptor de androgenos (sarms) | |
| AR073498A1 (es) | Derivados de tieno [2-3-d] pirimidin | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| BR112018073279A2 (pt) | dispersão aquosa, processo para preparação da dispersão aquosa, e, composição de proteção solar. | |
| ES2539722T3 (es) | Compuesto de tetrahidrobenzotiofeno | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR072428A1 (es) | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. | |
| AR043055A1 (es) | Derivados de 1-(4-benzil-piperazin-1-il)-3- fenil-propenona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |